Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 7OTHER 4NETWORK 3NIH 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 1FGFR1 Gene Amplification 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 171Vincristine 162Carboplatin 153Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 71Magnetic Resonance Spectroscopy 64Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × AZD4547 × Clear all
NCT01824901 2023-06-29

Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Completed
2 enrolled 4 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02154490 2023-06-01

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Completed
1,864 enrolled 12 charts

Recurrent Squamous Cell Lung Carcinoma

NCT02965378 2021-05-27

Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
43 enrolled 15 charts

FGFR1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡